
Results
15
Companies which are more than 50% undervalued based on analyst price target.
15 companies
Inventiva
Market Cap: €888.4m
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
IVA
€3.73
7D
13.9%
1Y
34.7%
Valneva
Market Cap: €433.0m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
VLA
€2.29
7D
1.9%
1Y
-10.3%
Cellectis
Market Cap: €192.1m
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
ALCLS
€2.70
7D
-5.2%
1Y
102.9%
Innate Pharma
Market Cap: €149.4m
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
IPH
€1.59
7D
-0.5%
1Y
5.3%
Sensorion
Market Cap: €128.7m
A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
ALSEN
€0.26
7D
1.8%
1Y
-20.9%
OSE Immunotherapeutics
Market Cap: €79.1m
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
OSE
€3.41
7D
8.5%
1Y
-32.9%
Adocia
Market Cap: €74.6m
A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.
ADOC
€3.93
7D
-8.2%
1Y
2.9%
ABIONYX Pharma
Market Cap: €65.4m
A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.
ABNX
€1.94
7D
-4.4%
1Y
60.3%
AB Science
Market Cap: €59.2m
A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.
AB
€0.75
7D
-2.2%
1Y
-46.1%
MaaT Pharma
Market Cap: €49.0m
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
MAAT
€2.70
7D
2.3%
1Y
-41.3%
THX Pharma Société Anonyme
Market Cap: €47.7m
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
ALTHX
€3.57
7D
7.9%
1Y
200.0%
Nicox
Market Cap: €33.7m
Operates as an ophthalmology company in France and internationally.
ALCOX
€0.39
7D
1.8%
1Y
71.4%
Advicenne
Market Cap: €24.4m
A specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally.
ALDVI
€1.60
7D
28.8%
1Y
17.6%
GenSight Biologics
Market Cap: €19.7m
A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
SIGHT
€0.083
7D
3.1%
1Y
-35.8%
Valbiotis
Market Cap: €19.0m
Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.
ALVAL
€0.78
7D
-5.9%
1Y
-7.9%